Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Transl Res. 2020 Jul 6;225:33–53. doi: 10.1016/j.trsl.2020.06.012

Table 3.

Biomarker studies assessing primary arterial thromboembolism risk in cancer patients

Biomarker Study Design Cancer Type Number of patients Biomarker Cutoff or Numeric Variable Statistic 95% CI Reference
Neutrophil count Prospective Mixed 1883 >4.9 × 109/l sHR 2.4 1.3‐4.6 228
Soluble P-selectin Prospective Mixed 1883 >46.3 ng/ml sHR 2.1 1.2‐3.8 228
D-dimer Prospective Mixed 1883 Per 2-fold increase sHR 1.1 0.9‐1.4 228
Neutrophil-to-lymphocyte ratio Prospective Mixed 1469 Per 2-fold increase sHR 1.2 0.9–1.6 114
Platelet-to-lymphocyte ratio Prospective Mixed 1469 Per 2-fold increase sHR 1.1 0.7–1.5 114
Citrullinated histone H3 Prospective Mixed 957 Per 100 ng/ml increase sHR 1.0* 0.7–1.4 229
Cell free DNA Prospective Mixed 957 Per 100 ng/ml increase sHR 1.0* 0.9–1.2 229
Nucleosome Prospective Mixed 957 Per unit increase sHR 1.1* 1.0–1.2 229
*

Denotes a univariable analysis. All other statistics are given for multivariable analyses. CI, confidence interval; sHR, subdistribution hazard ratio.